Date:11/12/2009

2009 2008 Sales, net $15,556,345 $7,541,534 $36,249,051 $23,772,567 Cost of sales 3,585,143 3,756,445 9,753,704 10,423,651 Gross profit 11,971,202 3,785,089 26,495,347 13,348,916 Selling, general and administrative expenses 7,857,258 3,126,704 14,608,550 8,553,999 Income from operations 4,113,944 658,385 11,886,797 4,794,917 Other Income (Expense) Interest income 488 841 981 2,362 Interest expense -- (10,463) -- (39,945) Loss on disposal of building -- -- (248,730) -- Foreign exchange loss -- -- (10) -- Total other Income (Expense) 488 (9,622) (247,759) (37,583) Income before income taxes 4,114,432 648,763 11,639,038 4,757,334 Provision for income taxes 988,286 89,580 2,828,683 619,055 Net income $3,126,146 $559,183 $8,810,355 $4,138,279 Net income per common share Basic $0.13 $0.03 $0.38 $0.19 Diluted $0.13 $0.02 $0.37 $0.18 Weighted average common shares outstanding Basic 23,240,899 22,152,311 23,240,899 22,152,311 Diluted 23,720,233 23,240,899 23,720,233 23,240,899 BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Nine Months Ended September 30, 2009
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
2. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. BioMarin Acquires Huxley Pharmaceuticals, Inc.
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
8. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
9. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
10. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.